Drug Profile
Research programme: second generation factor IX therapeutic - Bayer Schering Pharma
Latest Information Update: 21 Mar 2011
Price :
$50
*
At a glance
- Originator Bayer Schering Pharma
- Developer Bayer HealthCare Pharmaceuticals
- Class Blood coagulation factors; Peptide hydrolases
- Mechanism of Action Factor IX stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Haemophilia B
Most Recent Events
- 16 Sep 2008 Bayer Schering Pharma acquires DIREVO Biotech
- 16 Sep 2008 Preclinical trials in Haemophilia B in Germany (Parenteral)